Atea Pharmaceuticals
AVIR
108 hedge funds and large institutions have $194M invested in Atea Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 40 increasing their positions, 30 reducing their positions, and 11 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 30
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
3% more funds holding
Funds holding: 105 → 108 (+3)
1.29% more ownership
Funds ownership: 67.32% → 68.6% (+1.3%)
3% more capital invested
Capital invested by funds: $188M → $194M (+$6.36M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
96% less call options, than puts
Call options by funds: $88K | Put options by funds: $2.31M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$995K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$723K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$661K |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$473K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$460K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$603K |
| 2 |
BlackRock
New York
|
-$471K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$308K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$259K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$201K |
AVIR Hedge Fund Activity: Q3 2024 in Review
108 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q3 2024, worth a combined $194M — up 3.4% from $188M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AVIR positions and 11 closed out — a net gain of 3 holders — while 40 added to existing stakes and 30 trimmed.
The largest buyer was BML Capital Management, adding an estimated $995K. The largest seller was Marshall Wace, exiting entirely with an estimated $603K sold.
- 108 institutional investors held Atea Pharmaceuticals (AVIR) as of Q3 2024, up from 105 in Q2 2024.
- Funds reported $194M of Atea Pharmaceuticals stock for Q3 2024, up 3.4% quarter-over-quarter.
- 14 funds opened new Atea Pharmaceuticals positions in Q3 2024 and 11 closed out, a net change of +3 holders.
- The largest Atea Pharmaceuticals buyer in Q3 2024 was BML Capital Management, an estimated $995K added.
- The largest Atea Pharmaceuticals seller in Q3 2024 was Marshall Wace, an estimated $603K sold.
Based on aggregated 13F filings for Q3 2024.